Premium Synthetic Mazdutide Peptide Raw Material CAS:2259884-03-0 Rigorous HPLC-MS QC Testing & Stable Physicochemical Properties
TDS 5 Inquiries
2259884-03-0
Pharmaceutical Grade
99%
海南
SDR
Bottled
2027-01-27
peptides,Semagiutide,Retatrutide,GHK-CU,MOTS-c,Semax
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionMazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achieved 12-week body weight loss of up to 6.4% at doses up to 6 mg in Chinese adults with overweight or obesity. It is the first GLP-1R/GCGR dual agonist to succeed in Phase 3 trials. As mazdutide's first registrational trial for weight management, the results of GLORY-1 not only further confirm the efficacy and safety of the mazdutide in a large population but also provide high-quality clinical evidence of long-term pharmacotherapy weight management specifically for the Chinese population with overweight or obesity[1].Certificates
-
TDS
Basic Info-
Product Name:
Mazdutide
Other Name:Mazdutide;Mazdutide acetate;Mazdutide 10mg;Mazdutide 5mg 10mg;LY-3305677;Mazdutide (IBI-362;OXM-3)
CAS No.:2259884-03-0
Molecular Weight:0
EC Number:884-103-0
Color/Form:White to off-white
Categories:
Research-
Class:
Dual GLP-1R/GCGR agonist (long-acting peptide)
Status:Investigational — Phase 3 (China)
Mechanism:A long-acting dual agonist of the GLP-1 receptor (GLP-1R, Ki = 28.6 nM) and glucagon receptor (GCGR, Ki = 17.7 nM). The dual activation provides both glycemic control (via GLP-1R) and increased energy expenditure / hepatic lipolysis (via GCGR), producing weight loss beyond what GLP-1R agonism alone achieves. Administered once weekly.
EC50 (GLP1R Ki):28.6 nM
EC50 (GCGR Ki):17.7 nM
Source:GlpBio: Mazdutide (CAS 2259884-03-0); Innovent Phase Ib results (eClinicalMedicine 2022).DOI
Clinical Development:
References-
PubChem:Literature:
GlpBio: Mazdutide (CAS 2259884-03-0); eClinicalMedicine: Innovent Phase Ib results (2022); ClinicalTrials.gov: DREAMS-1 (NCT04930343)
Disclaimer:Mazdutide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials in China. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptides,Semagiutide,Retatrutide,GHK-CU,MOTS-c,Semax
-
Location:
Units 1503-14, 15th Floor, New HNA Building, No. 7 Guoxing Avenue, Lantian Subdistrict, Meilan District, Haikou City, Hainan Province
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
101-200
-
Year of Establishment:
2025
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Mazdutide
30 MG Jul 15, 2024
United States
Mazdutide
25 MG Aug 12, 2026 
Nigeria
Mazdutide 10mg
20 PCS Mar 7, 2026 
United Kingdom
Mazdutide
1 KG Feb 10, 2026
United States
Mazddultide cas
2 MT Nov 14, 2025 Post an enquiry for this product
